Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05508529 · ClinicalTrials.gov registry record · NA

Natural Modulators of Immune Function and Mood

A NA study of Stress, sponsored by 3 Waves Wellness.

Completed
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT05508529: Completed NA study of Stress, sponsored by 3 Waves Wellness.

NCT05508529 is a NA study of Stress that has completed, run by 3 Waves Wellness. The registered enrollment target is 120 participants, below the 785-participant average among 152 other Stress trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05508529, a NA study of Stress, has completed, sponsored by 3 Waves Wellness.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The objective of this proposal is to recruit 20 healthy subjects per ingredient arm (5 arms x 20 subjects; N= 120 total) to participate in a research study investigating the effects of dietary supplementation for one-month with different dietary supplement formulations (versus placebo; N=20) that may have benefits for supporting respiratory health, psychological stress, and quality of life. Supplements to be studied (all are commercially available): 1. Chaga (mushroom extract) 2. Arava (algae concentrate) 3. Thymoquin (black cumin seed oil) 4. Thymoquin + Astaxanthin (antioxidant carotenoid) 5. Thymoquin + Omega 3 (fish oil) 6. Placebo (corn starch) In order to "stress" volunteers, participants will train for and complete a strenuous off-road trail marathon to induce both physical and mental stress.

Primary Outcome

"Global Well-Being" index as collected by the validated Profile of Mood States Survey (POMS)

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Chaga Mushroom
  • DIETARY_SUPPLEMENT Algae Extract
  • DIETARY_SUPPLEMENT Black Cumin Seed Oil
  • DIETARY_SUPPLEMENT Black Cumin Seed Oil + Astaxanthin
  • DIETARY_SUPPLEMENT Black Cumin Seed Oil + Omega 3

Study Locations (1)

Massachusetts

  • 3 Waves Wellness, LLC - Plymouth

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2020-07-01
Est. Completion 2021-07-01
Phase NA
3 Waves Wellness

2 total trials

What the finished NCT05508529 record still lists

NCT05508529 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 785-participant average among 152 other Stress trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Stress appearing as the primary indexed condition, and to 5 interventions - of which Chaga Mushroom is the first listed.

NCT05508529 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05508529 about?

NCT05508529 is a clinical study titled "Natural Modulators of Immune Function and Mood". The objective of this proposal is to recruit 20 healthy subjects per ingredient arm (5 arms x 20 subjects; N= 120 total) to participate in a research study investigating the effects of dietary supplementation for one-month with different dietary supplement formulations (versus placebo; N=20) that ma...

What is the current status of trial NCT05508529?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2020-07-01. Estimated completion is 2021-07-01.

What conditions does trial NCT05508529 study?

This clinical trial studies the following conditions: Stress.

What interventions are being tested in trial NCT05508529?

The interventions under investigation include: Chaga Mushroom (DIETARY_SUPPLEMENT), Algae Extract (DIETARY_SUPPLEMENT), Black Cumin Seed Oil (DIETARY_SUPPLEMENT), Black Cumin Seed Oil + Astaxanthin (DIETARY_SUPPLEMENT), Black Cumin Seed Oil + Omega 3 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05508529?

This trial is sponsored by 3 Waves Wellness, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05508529 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stress

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05508529's enrollment target sits among peer trials

120 52nd of 152 higher than 94 of 152 other Stress trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stress trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05508529, the US trial registry maintained by the National Library of Medicine. NCT05508529 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.